UZH-Logo

Langwirksame Medikamente zur Behandlung der hyperkinetischen Störungen. Eine systematische Übersicht und europäische Behandlungsleitlinien Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate


Banaschewski, T; Coghill, D; Santosh, P; Zuddas, A; Asherson, P; Buitelaar, J; Danckaerts, M; Döpfner, M; Faraone, S V; Rothenberger, A; Sergeant, J; Steinhausen, H C; Sonuga-Barke, E J S; Taylor, E (2008). Langwirksame Medikamente zur Behandlung der hyperkinetischen Störungen. Eine systematische Übersicht und europäische Behandlungsleitlinien Teil 2: Ein quantitativer Vergleich der langwirksamen Präparate. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 36(2):97-106; quiz 106.

Abstract

A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorders, on the basis of which practical recommendations for the application of these medications have been developed. The current article outlines results of this analysis, comparing the effect sizes and numbers-needed to-treat for extended-release stimulant preparations and atomoxetine (ATX). It is concluded (1) that long-acting preparations should be licensed and used. (2) However, they should not completely replace short-acting medications, in view of costs as well as the greater flexibility of dosing. Individual choices of therapy are necessary. (3) Both ATX and retarded-release stimulants should be available.

A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorders, on the basis of which practical recommendations for the application of these medications have been developed. The current article outlines results of this analysis, comparing the effect sizes and numbers-needed to-treat for extended-release stimulant preparations and atomoxetine (ATX). It is concluded (1) that long-acting preparations should be licensed and used. (2) However, they should not completely replace short-acting medications, in view of costs as well as the greater flexibility of dosing. Individual choices of therapy are necessary. (3) Both ATX and retarded-release stimulants should be available.

Citations

7 citations in Web of Science®
7 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

128 downloads since deposited on 29 Dec 2008
14 downloads since 12 months
Detailed statistics

Additional indexing

Other titles:Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications
Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > Center for Child and Adolescent Psychiatry
Dewey Decimal Classification:610 Medicine & health
Language:German
Date:March 2008
Deposited On:29 Dec 2008 08:46
Last Modified:05 Apr 2016 12:37
Publisher:Hans Huber
ISSN:1422-4917
Publisher DOI:10.1024/1422-4917.36.2.97
PubMed ID:18622939
Permanent URL: http://doi.org/10.5167/uzh-6517

Download

[img]
Preview
Filetype: PDF
Size: 1MB
View at publisher

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations